A：The company delivered revenue of $16.6 billion, with growth across oncology and animal health and increasing contributions from recent launches. Investments in the next generation of innovative medicines and vaccines were mentioned, and the company remains confident in its outlook for the remainder of the year.

A：The FDA approved Lip FINRA, the first and only oral P inhibitor for hyperlipidemia in adults, and the company successfully worked with the FDA to bring this accelerated treatment option to patients. They also presented encouraging data for the durability of cotrubas at the American Society of Clinical Oncology (ASCO).

A：The company completed the acquisition of Kearns Pharmaceuticals, adding a novel potentially best-in-class therapy for certain patients with chronic myeloid leukemia to their hematology pipeline. Initial access plans for their investigational once monthly oral HIV prep candidate, Alamarivu, were announced, reflecting their commitment to advancing the treatment of HIV.

A：The CEO is proud that the company is successfully executing on its strategy, making important progress, and building a stronger foundation for the future. They are broadening their pipeline and achieving clinical, regulatory, and commercial milestones. The CEO believes that the company is stronger and better positioned for sustainable future growth than it was five years ago.

A：The company reported total company revenues of $16.6 billion, a 5% increase, or 4% when excluding the impacts of foreign exchange. Sales of Keytruda family of products increased 4% to $8.4 billion, with global growth driven by various factors such as strong uptake in earlier stage cancers and continued demand from metastatic indications. Sales in oncology were also strong, with Keytruda Qlex sales increasing significantly, and the broader oncology portfolio delivered another quarter of strong revenue growth.

A：ID Vizo, a once daily oral Ii drug for certain virally suppressed adults, has seen encouraging early progress on access and reimbursement. Global sales reached $588 million, a 75% increase, reflecting continued strong demand, particularly from adults with pulmonary arterial hypertension. In the U.S., more than 600 new patients received prescriptions, and the proportion of patients not on a prostacyclin background therapy increased. Outside the U.S., ongoing launches contributed to sales of $400 million, driven by prescription demand for COPD and timing of specialty pharmacy purchases.

A：Gross margin decreased by 1.1 percentage points to 81.1% primarily due to higher inventory reserves. Operating expenses increased to $12.6 billion, including a $5.7 billion charge for the acquisition of Terence Pharmaceuticals. Excluding these charges, operating expenses grew, reflecting investments in new product launches and the robust pipeline, partially offset by benefits from a multi-year optimization effort and external funding for certain projects.

A：The full year revenue guidance has been raised and narrowed to between $66.3 and $67.3 billion, indicating growth and a positive impact from foreign exchange. Gross margin is expected to be approximately 84.5%, operating expenses are between $42 and $42.7 billion, and a one-time tax-deductible charge is included. The full year tax rate is expected to be between 35 and 36%, with assumed shares outstanding of about 2.48 billion. Consequently, the expected EPS is between $2.66 and $2.76, with a midpoint at $2.71, incorporating a positive foreign exchange impact and the aforementioned upfront charge related to the acquisition of Turn.

A：Key considerations include the strong clinical profile of otev and its potential to achieve multi-billion dollar commercial success. Third quarter sales will be affected by the unwinding of specialty pharmacy purchases. Investments in the sales force and promotion are expected to lead to accelerated growth in 2027. For Keytruda, total U.S. year-over-year growth is anticipated to moderate as the company reaches peak penetration in several key indications. U.S. sales are expected to decline at a slower pace due to lower-than-anticipated generic competition. Other revenue is expected to be significantly higher in the second half of 2026 due to a revenue hedging program and a milestone receipt related to an out-licensing agreement.

A：The company's strategy remains focused on investing in near and long-term growth, including new product launches and the robust pipeline. A commitment to increasing the dividend over time and maintaining a strong investment-grade credit rating for pursuing science-driven, value-creating transactions is present. The goal is to achieve approximately $300 billion in share repurchases for the year, as previously communicated. As of the second half of 2026, the company remains confident in its business outlook, supported by global demand for innovative medicines and vaccines, and ongoing portfolio transformation.

A：In the second quarter, several important regulatory and clinical milestones were achieved. Notably, the FDA approval was received for Leandra, the first approved oral PCSK9 inhibitor. This approval is a major step in making PCSK9 inhibition more accessible as a convenient daily oral treatment. Additionally, the company is advancing combination approaches to further reduce LDL cholesterol and target additional cardiovascular disease risk factors. Updates on the HIV program were also provided, including new data presented at a major event and progress in the development of novel oral treatment options for those living with or at risk of HIV.

A：The phase 3 study of Mk 14 6, an investigational long acting, strain agnostic antiviral for preventing influenza, is progressing towards potential approval in 2029.

A：The Ssc ILD study did not meet its primary endpoint in hydroides supraorbital. However, the study met its primary and key secondary endpoints, which signifies a successful phase in the broader Phase Ii development program to explore the hypothesis of targeting T1A.

A：The National Priority Review Voucher for Sacituzumab will be applied towards the endometrial cancer filing. The readout from the global Troph 005 program is anticipated to pursue first mover opportunities and establish early leadership in breast and non-small cell lung cancer.

A：The anticipated timeline for key events and milestones in the second half of the year includes updates on September 21 for the label update based on the Phase 3 Hyperion study in Immunology for Tulus Bocar, second readout from the Atlas UC trial, presentation of data from the Phase 2 HS study in ophthalmology, and Phase 3 Granilla study of Retromag, among others.

A：The prospects for Sac TMT in first line therapy and potential combinations with other immunotherapies such as Pembro and APD1 are positive, with signals observed regardless of PDL1 expression and plans to re-evaluate Keynote 189 which combines true with chemotherapy. Additionally, there are plans to develop Sac TMT as a next-generation chemo-adjacent agent.

A：The significance of the Phase 3 results from the Global Fusion Development program lies in their validation of the strategy to pursue first mover opportunities and establish early leadership in breast and non-small cell lung cancer. These results will influence future trials and approvals by informing the initiation of trials that can proceed from phase 2 to phase 3 seamlessly.

A：Biomarkers are being considered in the development strategy to determine the necessity and to understand the role of the biomarkers in advancing the strategy. The company has clear biomarker data suggesting which indications to pursue, such as in the case of T1A for rheumatoid arthritis. They are looking at how the drug performs in various patient populations and in combination with other treatments like anti-Tang therapies. However, a negative result in a specific patient population may make it challenging to demonstrate benefit in a treatment setting.

A：The results from Study 1 are crucial as they will, together with other phase III studies, form the package to be sent to the FDA. There is a clear signal in Crohn's disease, supported by the company and others. The company is particularly interested in the outcomes of phase II studies and the potential to advance the drug further. They also see a fibrosis component in relation to other indications discussed. The company acknowledges the complexity of Crohn's disease as a refractory condition and the importance of evaluating the placebo effect carefully. If there is no progression in the placebo arm, it may affect the chances of demonstrating treatment benefit.

A：The company is pleased with the initial market access pace and the clean label for the new drug. There is significant interest from both physicians and patients, and ordering has begun. Although access is expected to take time to establish, the company is optimistic about the drug becoming a meaningful treatment and a blockbuster in the future. Discussions with the administration indicate a desire to use the drug as a cornerstone for priority review programs, touching on multiple pillars such as public health, chronic disease treatment, supply chain resilience, and increasing accessibility.

A：The company is focused on growth and is confident in the earnings profile for the next few years, although specific guidance from 2028 through early periods was not provided in the transcript. The focus is on the long-term prospects of the company and the potential of the new product to contribute to earnings. However, the timeline for market access and the pace of revenue growth were acknowledged as factors that could influence the earnings profile over time.

A：The biggest risk to achieving the $70 billion potential opportunity is not specified in the transcript.

A：The programs that have increased in confidence based on the performance so far include those that are already showing positive data, with many of them being part of the 10 programs representing 70% of the $70 billion potential opportunity. Notably, an accelerated launch of one of these products, levenda, by several months is mentioned as an example of successful programs.

A：The company's strategy for evaluating potential combination approaches involves focusing on PD-1 Vf in areas where there is an overlap of activity between PD-1 and VEGF, as well as unique assets that can be combined where such activity is known to occur.

A：The company views GL-1a as a competitive single agent in terms of its activity in relation to PD-1, and the competitiveness is evaluated based on an overlap with where PD-1 is active and the unique assets the company has.

A：The company aims to ensure a clean safety profile for their combinations by focusing on the safety profile of their 1a and its ideal combination for each indication. This is important to enable the possibility of combinations in various indications such as I, H, and others.

A：The timing for the Leandra CVOT is pending as the question was raised but not answered in the transcript. The impact of a potential drop in the use of incretin for weight loss on the results is also pending as the transcript does not provide a clear answer to how such usage could be balanced across arms if it happens.